// App-Quantinova.ai

975 : Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

Researchers

Presenter

  • Paul Newcombe

Principal Investigators

  • Richard A. Furie

  • Yoshiya Tanaka

  • Wendy White

  • Dominic Sinibaldi

  • Philip Brohawn

  • Mark Lazarus

  • Nicola Ferrari

  • Raj Tummala

  • Hussein Al-Mossawi

  • Andre Nogueria da Costa

  • Daniel Muthas

  • Madhu Ramaswamy

Medical Centers

  • Astra Zeneca, Cambridge, United Kingdom

  • Northwell Health, Great Neck, NY

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • AstraZeneca, Gaithersburg, MD

  • AstraZeneca, Gothenburg, Sweden

Locations

  • United Kingdom

  • United States

  • Japan

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • MDX1333

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacodynamics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved